Get 40% Off
👀 👁 🧿 All eyes on Biogen, up +4,56% after posting earnings. Our AI picked it in March 2024.
Which stocks will surge next?
Unlock AI-picked Stocks

UPDATE 2-Canada, biggest provinces promise new steps to fight second COVID wave

Published 2020-09-29, 01:07 p/m
Updated 2020-09-29, 02:48 p/m

(Recasts lead, adds details, background)

By Allison Martell

TORONTO, Sept 29 (Reuters) - Canada's federal authorities and its two biggest provinces on Tuesday promised new measures to combat a second COVID-19 wave that is notching up as many cases as during the pandemic's peak in April.

Canada reported new 2,176 infections on Monday, taking the total to 155,301. The death toll rose by 10 to 9,278.

Government minister Dominic LeBlanc, who chairs the cabinet's coronavirus committee, called the surge "very worrying".

Ontario, the most populous of the 10 provinces, said it would limit visitors to long-term care homes for the elderly in areas with high community spread. Most deaths in Canada have taken place in homes for seniors.

In Quebec, the second most populous, premier Francois Legault said financial support for businesses hurt by new COVID-19 restrictions would be announced soon. The province is closing bars and dine-in services at restaurants in hot spots for 28 days.

"The situation is still critical,” Legault told reporters in Quebec City.

In Ottawa, health officials said they expected to authorize new antigen tests for COVID-19, which can provide rapid results outside of a lab. This should provide additional testing as the second wave overwhelms laboratories, they said.

Prime Minister Justin Trudeau, who last week said the government would provide C$440 million ($329 million) to a global program designed to ensure fair access to COVID-19 vaccines, on Tuesday said Canada was giving an additional C$400 million in humanitarian and development funding.

Separately on Tuesday, the federal government said it had signed an agreement up to buy 7.9 million Abbott ABT.N ID NOW rapid point of care tests, pending Health Canada approval.

3rd party Ad. Not an offer or recommendation by Investing.com. See disclosure here or remove ads .

The ID NOW is not an antigen test, but the instruments used to analyze it can be run outside of a major lab, giving rapid results at a clinic or hospital. ($1 = 1.3385 Canadian dollars) (With additional reporting by David Ljunggren and Steve Scherer in Ottawa, Allison Lampert in Montreal and Moira Warburton in Vancouver, writing by David Ljunggren; Editing by Bernadette Baum, David Gregorio and John Stonestreet)

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.